ALS antisense drug falters in phase III

Biogen and Ionis's SOD1-antisense oligonucleotide tofersen failed a first phase III trial, raising questions about the next steps for this drug and for future ALS trials.

Automated summary

The SOD1-antisense oligonucleotide tofersen, developed by Biogen and Ionis, failed a phase III trial, prompting concerns about the drug's future and the direction of ALS trials to come.